^
Association details:
| Biomarker: | ERBB3 V104L + HER-2 negative |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib–Irinotecan Combo: A Case Study
Published date:
01/18/2021
Excerpt:
...we present the case of a 69-year-old man with advanced gastric cancer whose tumor was negative for human epidermal growth factor receptor 2 (HER2)...Next-generation sequencing...indicated the presence of the ERBB3 V104L mutation. The patient received irinotecan plus pyrotinib as a third-line therapy and achieved a progression-free survival of 7.6 months with a high quality of life.
Secondary therapy:
irinotecan
